Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin-Reference-Cited by-全球学者库

Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin

Published:2022-12-22 Issue:2 Volume:43 Page:246-256
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Zhao Yuanyuan¹^ORCID,Zhao Bing²,Chen Gang¹,Chen Yinlan³,Liao Zijun⁴,Zhang Haiming⁵,Feng Weineng⁶,Li Yinyin⁷,Weng Heng⁸,Li Weidong⁹,Zhou Yuefen¹⁰,Ren Biyong¹¹,Lu Yanda¹²,Chen Jianhua¹³,Liu Zhenteng¹⁴,Su Zhenzhong¹⁴,Wang Wenliang¹⁴,Zhang Li¹

Affiliation:

1. Department of Medical Oncology Sun Yat‐sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong P. R. China

2. Department of Day Ward First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang P. R. China

3. Department of Medical Oncology Jiangxi Cancer Hospital Nanchang Jiangxi P. R. China

4. Department of Medical Oncology Shaanxi Provincial Cancer Hospital Xi'an Shaanxi P. R. China

5. Department of Medical Oncology The First People Hospital of Xiangtan Xiangtan Hunan P. R. China

6. Department of Medical Oncology The First People Hospital of Foshan Foshan Guangdong P. R. China

7. Department of Medical Oncology Shenyang Tenth People's Hospital Shenyang Liaoning P. R. China

8. Respiratory Medicine Fuzhou Pulmonary Hospital of Fujian Fuzhou Fujian P. R. China

9. Department of Medical Oncology Affiliated Cancer Hospital & Institute of Guangzhou Medical University Guangzhou Guangdong P. R. China

10. Department of Medical Oncology The Central Hospital of Lishui Lishui Zhejiang P. R. China

11. Department of Medical Oncology Chongqing Three Gorges Central Hospital Chongqing P. R. China

12. Department of Medical Oncology The First Affiliated Hospital of Hainan Medical University Haikou Hainan P. R. China

13. Department of Medical Oncology Hunan Province Tumor Hospital Changsha Hunan P. R. China

14. Institute of Materia Medica Luoxin Pharmaceutical Group Co., Ltd Shanghai P. R. China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12397

Reference24 articles.

1. Delayed Nausea and Vomiting Continue to Reduce Patients' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment

2. Antiemetics: ASCO Guideline Update

3. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

4. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting

5. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents;Supportive Care in Cancer;2023-12-21